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EXPERT REVIEWManagement of antiplatelet therapy resistance in cardiac surgeryHrvoje Gasparovic, MD, PhD, Mate Petricevic, MD, and Bojan Biocina, MD, PhDThe role of coronary artery bypass grafting (CABG) in the
management of complex coronary artery disease has been
validated through an unparalleled level of scrutiny.
Improvement in patient outcomes currently relies on
continued refinements of the surgical technique and modu-
lation of adjuvant pharmacotherapy. Postoperative anti-
platelet therapy (APT) is paramount in maintaining the
revascularization benefit. However, individual variability
to APT results in unpredictable platelet inhibition.
Currently available platelet function tests (PFTs) dichoto-
mize patients into ‘‘responders’’ and ‘‘nonresponders’’ on
the basis of arbitrarily defined cutoff points. It is not surpris-
ing that the incidence of APT resistance across the spectrum
of PFTs is widely discrepant, underscoring the fact that sin-
gle pathway descriptors of platelet aggregation fail to
portray the complexity of the process. Thrombosis is the
principal mode of failure of saphenous vein grafts (SVGs)
in the early postoperative period.1 Reports on the increased
incidence of SVG failure in patients experiencing antiplate-
let agent resistance underscore the importance of recog-
nizing this entity and intervening in a timely fashion. This
review summarizes the various assay-dependent definitions
of APT resistance, with their respective rates of occurrence.
The clinical impact of on-therapy high residual platelet
reactivity (hRPR) in the cardiac surgical arena is discussed.
Finally, guidelines on individual tailoring of APT in patients
found to retain high on-therapy platelet reactivity are
suggested.MATERIALS AND METHODS
The PubMed database was searched using the following subject terms:
platelet function testing, antiplatelet, aspirin, clopidogrel, resistance, and
cardiac surgery. Reference lists of identified publications were analyzed
for additional linking studies. Priority was given to cohort studies and
reviews.
Definition of Antiplatelet Therapy Resistance
Aspirin is the most commonly used antiplatelet agent after CABG.
Its use is associated with a 40% reduction in bypass graft occlusions,2
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The Journal of Thoracic and Caof SVG occlusions within the first year, when the impact of
thrombosis is greatest, range from 7.4% to 26%.5-7 This angiographic
outcome is accompanied by a 20% to 30% reoccurrence of angina8
and a 5.9% need for repeat revascularization within the first year.9
The current guidelines on postoperative APT recommend the initiation
of 100 to 325 mg of aspirin within 6 hours of surgery.10 In patients
unable to take aspirin, 75 mg of clopidogrel is the suggested
alternative.10
The importance of prompt postoperative institution of aspirin is under-
scored by the fact that starting aspirin on the third postoperative day or later
is unlikely to reflect favorably on graft patency.11,12 However, the one-size-
fits-all recommendation for perioperativeAPT in the current guidelines dis-
regards the individual response variability.
The term aspirin resistance denotes the drug’s inability to effectively
suppress cyclooxygenase-1–dependent thromboxane A2 (TxA2) pro-
duction. Aspirin’s failure to act on its pharmacologic target originates
from variable enteral absorption, cyclooxygenase 1 gene mutations,
drug–drug interactions, patient noncompliance, accelerated postcardio-
pulmonary bypass platelet turnover, and TxA2-independent platelet
activation pathways.13,14 The prevalence of aspirin resistance varies
widely in the literature because of variable platelet agonists used in
testing and different aspirin-related platelet function descriptors
(Table 1).
Clopidogrel is an inactive prodrug that undergoes extensive conversion
into its active metabolite by the hepatic cytochrome P450 (CYP) 3A4
enzyme.15 It irreversibly inhibits the P2Y12 adenosine diphosphate
(ADP) receptor, which is one of the pivotal routes of platelet activation.
Difficulties in elucidating the true incidence of clopidogrel resistance par-
allel those for aspirin, because it is also assay-dependent. P2Y12 receptor,
ABCB1, and CYP2C19 genetic polymorphisms affect clopidogrel pharma-
codynamics.15,16 Strategies moving beyond phenotype-directed into
genotype-directed tailoring of APT have become available, but they
currently lack validation in larger trials.16 Clopidogrel’s metabolic activa-
tion also is altered by medications acting as substrates for CYP3A4. Signif-
icant reductions in the clopidogrel-induced inhibition of platelet
aggregation have been noted in patients using atorvastatin and proton
pump inhibitors. Conflicting data on the clinical relevance of such interac-
tions have been published.17-22 Antiplatelet agent response is best
perceived as a continuous variable. However, the efficacy of APT may
be assessed in relation to cutoff points discriminating between
‘‘resistance’’ and ‘‘response,’’ or by measuring the on-therapy percent
platelet inhibition and comparing it with values obtained before APT.
The drawback of the latter strategy is that it is affected by variability in
baseline platelet reactivity. In contrast, strict cutoff values are invariably
arbitrarily defined but do allow for comparing outcomes in a binary model.
The definition of antiplatelet agent resistance remains a moving target.
Lordkipanidze and colleagues23 compared 6 different PFTs to determine
the prevalence of aspirin resistance and found a poor mutual correlation be-
tween individual tests. A succinct overview of the cutoff points defining an-
tiplatelet agent resistance using different PFTs is presented in Table 1.
Distinguishing between cardiac surgical patients in whom APT resistance
is permanent from those in whom it may be a temporary phenomenon may
hold practical value. The distinction between the 2 can be made by
comparing preoperative with postoperative PFT results. In patients found
to have on-therapy hRPR preoperatively, the resistance is likely a perma-
nent one. Conversely, adequate preoperative platelet inhibition followed
by early postoperative hRPR may suggest that the phenomenon is transient
in nature. Our group has shown a consistent increase in postoperative
platelet reactivity evaluated with aggregometry in comparison withrdiovascular Surgery c Volume 147, Number 3 855
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ADP ¼ adenosine diphosphate
APT ¼ antiplatelet therapy
BOCLA-Plan ¼ BOchum CLopidogrel and
Aspirin Plan
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CYP ¼ cytochrome P450
dAPT ¼ dual antiplatelet therapy
HR ¼ hazard ratio
hRPR ¼ high residual platelet reactivity
PFT ¼ platelet function test
SVG ¼ saphenous vein graft
TxA2 ¼ thromboxane A26 The Journapreoperative values,24 which is suggestive of heightened platelet reactivity
induced by surgery.
Clinical Impact of Antiplatelet Therapy Resistance
Aspirin-resistant TxA2 synthesis has been found to elevate the risk of
stroke, myocardial infarction, and cardiovascular death in patients with car-
diovascular disease.25 A graded increase in the aforementioned risk was
observed with each increasing quartile of urinary 11-dehydro thromboxane
B2, which is a metabolic surrogate of TxA2 activity.25
Investigators in the prevention of Coronary arteRY bypaSS occlusion
After off-pump procedures (CRYSSA) trial noted an alarming correlation
between graft occlusion and APT resistance (relative risk, 3.6; 95% confi-
dence interval [CI], 2.5-6.9;P<.001).5 Conversely, synergistic aspirin- and
clopidogrel-induced platelet inhibition was found to predict SVG patency
(relative risk, 5.1; 95% CI, 1.4-16.3; P<.01).5 The link between SVG oc-
clusion and platelet hyperreactivity on aspirin was reported as the second-
ary objective of the Reduction in Graft Occlusion Rates study.13 A higher
incidence of early SVG occlusion was found in patients taking aspirin who
had increased levels of urinary 11-dehydro thromboxane B2 and shear-
dependent platelet activation.13
Clopidogrel resistance also has been found to be clinically significant by
several investigators. Adverse cardiovascular events adjudicated at 6
months were found to be more common in clopidogrel-resistant patients
undergoing primary angioplasty for acute myocardial infarction.26 High
platelet reactivity to ADP on dual antiplatelet therapy (dAPT) increased
cardiovascular mortality (hazard ratio [HR], 2.55; 95% CI, 1.08-6.07; P
< .034) and nonfatal myocardial infarction (HR, 3.36; 95% CI, 1.49-
7.58; P< .004) at 12-month follow-up in a similar clinical setting.27 A
more comprehensive overview of the clinical impact of APT resistance is
provided in Table 1. Clopidogrel cessation is advocated in anticipation of
elective cardiac surgery to minimize perioperative blood loss.10 One
must recognize that this is potentially hazardous because it may induce a
rebound prothrombotic and proinflammatory state.28 Mahla and col-
leagues29 proved that clopidogrel can be continued safely up to surgery
provided that residual on-therapy platelet reactivity evaluated by throm-
boelastography remained high. Analogously, Di Dedda and colleagues30
recently documented that 32% of patients scheduled for cardiac surgery re-
tained hRPR on clopidogrel. These observations again add credence to
APTmonitoring, because it may directly influence the preoperative discon-
tinuation of clopidogrel and possibly lead to a revision of current
guidelines.l of Thoracic and Cardiovascular SurgManagement Options for Antiplatelet Agent
Resistance
With the problem of antiplatelet agent resistance lacking a clear outline
and definition, it is not surprising that guidelines for its management remain
to be formed. Although a large proportion of the evidence examining the
impact of APT resistance is observational in nature or comes from the
nonsurgical arena, there are 2 prospective randomized trials that will pro-
videmore data on the augmentation ofAPTin drug-resistant patients under-
going CABG.31,32 The former31 has reached the data-analysis stage,
whereas the latter32 is still recruiting patients. Coronary bypass grafts
may be especially vulnerable in the immediate postoperative period, and
there is growing evidence that APT resistance should not be ignored. The
first step in individualized tailoring of platelet inhibition should be PFTs
at approximately 7 days of APT initiation (Figure 1). Once hRPR is recog-
nized, extrinsic factors should be ruled out, such as patient noncompliance,
drug interactions or suboptimal glucose, and cholesterol regulation.
Because antiplatelet drug resistance may be a temporary manifestation,
one course of action is to reevaluate the drug effect without changing the
current platelet inhibition regimen. Within 7 days, both aspirin and unbo-
lused clopidogrel reach steady-state drug levels. Therefore, we recommend
repeating PFTs 7 days after any PFT result that is outside the desired ther-
apeutic window.
A significant proportion of patients recognized as clopidogrel resistant
24 hours after its institution were found to respond to the drug when reeval-
uated at 30 days.33,34 Likewise, the proportion of patients undergoing
CABG who were found to be aspirin resistant is inversely proportional to
the time elapsed between its assessment and the procedure itself.35,36
This point again brings into focus the importance of isolating patients
with permanent postoperative APT resistance from those with transient
postoperative APT resistance. In the event that a follow-up evaluation of
platelet function shows persistence of low responsiveness, different lines
of management should be explored.
An effective approach to APT resistance is to increase the drug dose. In
diabetic patients found to be hyporesponsive to 100 mg of aspirin,
increasing the dose to 300 mg led to superior platelet inhibition (platelet
function analyzer closure time increased from 170  45 seconds to 229
 75 seconds, P<.001).37 Increased loading andmaintenance doses of clo-
pidogrel also have been found to surmount the resistance to lower-dose
therapy.15,38 Doubling the dose of clopidogrel in patients found to be
nonresponders to 75 mg effectively inhibited platelets in 60% of
patients.39 Neubauer and colleagues38 reduced the incidence of clopidogrel
resistance from 23.6% to 5% by modification of the administered dose
based on an aggregometer-guided algorithm. However, the conversion of
nonresponders using this strategy remains unpredictable, which empha-
sizes the need for reevaluating the effectiveness of platelet inhibition after
the implemented dose change.39 The BOchum CLopidogrel and Aspirin
Plan (BOCLA-Plan) incorporating a ‘‘test and treat’’ strategy effectively
eliminated aspirin resistance by dose modification and subsequent PFT.40
Of the 19.4% patients found to be low-responsive to 100 mg of aspirin,
94.6% were converted to responders by increasing the dose to 300 mg.40
The remaining 5.4% received effective platelet inhibition by further
increasing the dose to 500 mg of aspirin.40 However, it is important to
acknowledge the potential of high-dose aspirin to worsen endothelial-
mediated arterial dilatation.41 A similar protocol was implemented for
the 30.8% of patients found to be resistant to 75 mg of clopidogrel.
Increasing the dose to 150 mg, in line with the predefined BOCLA-Plan,
induced effective platelet inhibition in 69% of previously resistant
patients.40
Finally, an attractive solution to the problem of hRPR on 1 platelet in-
hibitor is to add a different agent to induce an additive effect or to substitute
the original drug altogether. The different mechanisms of platelet inhibition
targeted by aspirin and thienopyridines allow for accumulation of their in-
dividual anti-aggregational effects. Mannacio and colleagues5 showed that
dAPT effectively overcame single drug resistances, with a subsequentery c March 2014
Gasparovic et al Expert Reviewreduction in SVG occlusion (7.4% vs 13.1%; P ¼ .04). Patients random-
ized to dAPT in the CRYSSA trial experienced similar rates of both minor
(2% vs 1.3%, P ¼ .5) and major bleeding episodes (1.3% vs 1.3%, P ¼
1.0) in comparison with the aspirin-monotherapy group.5 The safety of
dAPT was corroborated by similar chest tube outputs in both treatment
arms (115 80mL in the aspirin group vs 125 70mL in the dAPT group;
P ¼ .2).5 The administration of clopidogrel on the background of aspirin
therapy in the early postoperative period did not increase the rate of reex-
ploration or transfusion in a study by Chan and colleagues.42 Commonly
used protocols include starting dAPT when chest tube drainage has been
50 mL or less for 2 hours.5,42 However, we would recommend exercising
caution in restarting clopidogrel in patients taking preoperative dAPT
with documented profound ADP inhibition. Our group has documented
that preoperative Multiplate ASPI test (Dynabyte Gmbh, Munich,
Germany) values less than 20 area under the curve units and ADP test
less than 73 area under the curve units predicted higher postoperative
chest tube output.43
Although clopidogrel and aspirin account for the most commonly used
combination of antiplatelet drugs, the potential advantages of novel agents
may lead to a future revision of that paradigm. New-generation P2Y12 in-
hibitors are less susceptible to genetic polymorphisms.
Clopidogrel requires 2 CYP-mediated oxidative steps to reach its active
metabolite, whereas prasugrel requires only 1. It initiates faster and more
potent platelet inhibition, with less interpatient response variability than its
predecessor.44 The Trial to Assess Improvement in Therapeutic Outcomes
by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis In Myocar-
dial Infarction 38 demonstrated prasugrel’s superiority over clopidogrel in
the reduction of major adverse cardiovascular events in patients with acute
coronary syndromes (HR, 0.81; 95% CI, 0.73-0.90; P<.001).45 The reduc-
tion inmajor adverse cardiovascular events was offset by an increased risk of
bleeding.45 The post hoc analysis of patients in the prasugrel treatment arm
who underwent CABG mirrored the general study population’s increased
bleeding risk.46However, overall mortalitywas significantly lower in the pra-
sugrel than in the clopidogrel CABG cohort despite comparable risk profiles
(adjusted odds ratio, 0.26; 95%CI, 0.08-0.85; P¼ .025).46 A potential prob-
lem in interpreting these results is that all-cause mortality was as high as
8.67% in the clopidogrel cohort,which had ameanEuropeanSystem forCar-
diac Operative Risk Evaluation of only 3.6  3.2.46 This caveat is amplified
by the fact that European System for Cardiac Operative Risk Evaluation may
even overestimate CABG mortality.46,47 Nevertheless, prasugrel’s highly
effective platelet inhibition and low incidence of nonresponsiveness make
it a suitable candidate for patients found to be resistant to prior APT. In the
BOCLA-Plan, patients found to be clopidogrel resistant to even an
augmented dosing regimen benefited from the addition of prasugrel in
achieving the targeted antiplatelet effect.40
Ticagrelor is absorbed as an active agent and is therefore unaffected by
the idiosyncrasies of intrinsic biotransformation. Its prompt and reversible
P2Y12 inhibition was responsible for a significant reduction in adverse
events in its direct comparison with clopidogrel in the Study of Platelet In-
hibition and Patient Outcomes (HR, 0.84; 95% CI, 0.77-0.92; P<.001).48
The ticagrelor cohort had a 22% relative reduction in mortality.48 The inci-
dence of bleeding in the CABG subgroup was not affected by ticagrelor,
presumably because of the reversible nature of its P2Y12 inhibition.
48 It
has already been shown to be useful in upgrading APT in patients found
to be clopidogrel hyporesponders.49 In the Response to Ticagrelor in Clo-
pidogrel Nonresponders and Responders and Effect of Switching Therapies
trial, it has provided more uniform and enhanced platelet inhibition in com-
parison with clopidogrel, practically eliminating on-therapy hRPR.49
Prompt induction of platelet inhibition can be achieved with cangrelor.
It is a direct-acting P2Y12 inhibitor that immediately suppresses platelet ag-
gregation.50 Its effect is quickly reversible on the drug’s discontinuation.50
Cangrelor’s intravenous mode of administration overcomes the variability
in enteral absorption and bioavailability seen in patients with acute hemo-
dynamic compromise.51 In addition, its short half-life (3-5 minutes) allowsThe Journal of Thoracic and Cafor precise bridging of APT in patients scheduled for elective cardiac sur-
gery, without increasing the risk of major bleeding.52 Although the pharma-
cokinetic properties of cangrelor make it unsuitable for long-term
management of APT resistance, its potential applicability in the acute peri-
operative setting warrants mentioning.
Redundancy and parallel activation pathways characterize clot forma-
tion. The role of thrombin in the process of thrombosis goes beyond the
generation of fibrin, because it is a potent platelet agonist. Its platelet acti-
vation effects are mediated by protease-activated receptor 1.53 Vorapaxar is
a novel antiplatelet agent that inhibits platelet aggregability by targeting
protease-activated receptor 1. In the Thrombin Receptor Antagonist in Sec-
ondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in
Myocardial Infarction 50 trial, vorapaxar reduced the incidence of death or
adverse ischemic events over placebo on the background of standard ther-
apy (HR, 0.87; 95% CI, 0.80-0.94; P< .001).53 It increased the risk of
bleeding, including intracranial hemorrhage.53 Exploiting alternative
routes of platelet inhibition may be reasonable in patients found to be resis-
tant to the more commonly targeted platelet receptors.
Because the activation of clopidogrel is dependent on CYP3A4, it
stands to reason that pharmacologic induction of this enzyme’s metabolic
activity may convert clopidogrel nonresponders into responders.54 Co-
administration of rifampin and clopidogrel has been used to explore and
prove this concept in healthy volunteers.54 Whether this approach is of
any value in the cardiac surgical population is as of yet unknown.DISCUSSION
Despite the absence of an all-encompassing method for
defining antiplatelet response, there is sufficient evidence to
support wider dissemination of tools designed to quantify
on-therapy platelet reactivity. Strategies using PFTs to guide
transfusion therapy, reduce bleeding, and tailor APTare gain-
ing momentum in the modern cardiac surgical practice.55,56
Platelet aggregability after cardiac surgery is inconsistent
over the early postoperative period. Its unpredictable nature
stems from the integration of several opposing influences.
The effects of postoperative platelet depletion and
iatrogenic platelet inhibition are counterbalanced by
accelerated postcardiopulmonary bypass platelet turnover.
Therefore, longitudinal follow-up of platelet reactivity is a
useful adjunct to standard postoperative protocols aiming
to achieve optimal patient outcomes.
APT resistance may offset the benefits of surgical
myocardial revascularization. Point-of-care PFTs provide
timely information regarding residual platelet reactivity.
Unfortunately, individual PFTs provide data that are not al-
ways reciprocated by other tests. This brings into focus the
need for standardization and clinical validation of each test.
It is unlikely that different PFTs will ever provide
completely interchangeable results because of the large
variability of platelet activation pathways that are being
tested. Recognizing the impact of APT resistance should
serve as an impetus for the definition of its management al-
gorithms. Although APT resistance after cardiac surgery
may be a transient phenomenon, it occurs during the period
when graft patency is most vulnerable. dAPTor incremental
drug increases in conjunction with regular PFTs are useful
in overcoming this problem. The contemporary expansionrdiovascular Surgery c Volume 147, Number 3 857
TABLE 1. Antiplatelet therapy resistance: Assay-specific definitions, prevalence, and clinical impact
Study Patient population
Aspirin resistance Clopidogrel resistance
Incidence Platelet function test
POC
turnaround time Incidence
Mannacio and colleagues5 OPCAB (n ¼ 300) 32.6% (5 d after treatment initiation) VerifyNow Aspirin (Accumetrics Inc,
San Diego, Calif)
<10 min 22%* (5 d after
treatment initiation)
Sambu and colleagues57 Stent thrombosis (n ¼ 39) 28% (at inclusion) Short TEG (Haemonetics Corp,
Braintree, Mass)
15 min 67%y (at inclusion)
Gluckman and colleagues13 CABG (n ¼ 229) 5% (at 3 d postoperatively); 0.9% (at
6 mo postoperatively)
AA-induced platelet aggregometry
(Chrono-Log Corp, Havertown, Pa)
7 min Not reported
16% (at 3 d postoperatively); 10% (at
6 mo postoperatively)
VerifyNow Aspirin <10 min
64% (at 3 d postoperatively); 12% (at
6 mo postoperatively)
PFA-100 CEPI 5-8 min
73% (at 3 d postoperatively); 31% (at
6 mo postoperatively)
UTxB2 N/A
Petricevic and colleagues24 CABG (n ¼ 99) 31.3% (preoperatively); 46.5% (at
4 d postoperatively)
Multiplate ASPI test (Dynabyte Gmbh,
Munich, Germany)
9 min Not reported
Preisman and colleagues58 CABG (n ¼ 59) 44% (preoperatively) TEG platelet mapping (Haemoscope
Corp, Niles, Ill)
Up to 1 h 85% (preoperatively)
Lordkipanidze and
colleagues23
Stable coronary
disease (n ¼ 201)
4% LTA (AA) N/A Not reported
10.3%-51.7% LTA (ADP) N/A
18% Whole blood aggregometry (Chrono-
Log Corp)
7 min
59.5% PFA-100 5-8 min
6.7% VerifyNow Aspirin <10 min
22.9% UTxB2 concentration N/A
Kempfert and colleagues59 CABG/OPCAB (n ¼ 59) 28.8% (preoperatively); 49.2% (at
5 d postoperatively)
Turbidimetric aggregometry (PAP-4;
Moelab, Berlin, Germany)
N/A Not reported
Bednar and colleagues60 CABG/OPCAB (n ¼ 80) Not reported PAP-4 Platelet Aggregation Profiler
(BioData Corp, Horsham, Pa)
N/A Not reported
Poston and colleagues61 OPCAB (n ¼ 76) 3% preoperatively; 13.2%
postoperatively (at
3 d postoperatively)
TEG platelet mapping (Haemoscope
Corp)
Up to 1 h Not reported
Whole blood aggregometry (Chrono-
Log Corp)
7 min Not reported
Di Dedda and colleagues30 Cardiac surgery (n ¼ 344) Not reported Not reported N/A 32% preoperatively
AA, Arachidonic acid; ADP, adenosine diphosphate; APT, antiplatelet therapy; ASA, acetylsalicylic acid; AUC, area under the curve; CABG, coronary artery bypass grafting;
CADP, collagen/adenosine-50-diphosphate closure time; CEPI, collagen and epinephrine; CI, confidence interval; LTA, light transmittance aggregometry; MAadp, maximal
amplitude (clot strength assessed after addition of adenosine diphosphate); N/A, not available; OPCAB, off-pump coronary artery bypass;%MAASA, percentage change effect of
acetylsalicylic acid on maximum amplitude in arachidonic acid activated samples; POC, point-of-care; PFA, platelet function analyzer; RR, relative risk; SD, standard deviation;
SVG, saphenous vein graft; TEG, thromboelastography; TXA2, thromboxane A2; UTxB2, urinary 11-dehydro thromboxane B2; WBA, whole blood aggregometry; PAP, platelet
aggregation profiler; ASPI, platelet function test using arachidonic acid as an agonist.*In CRYSSA, 12.6% of patients were resistant to both aspirin and clopidogrel. yIn the
Clopidogrel Resistance in Stent Thrombosis study, 26% of patients were resistant to both aspirin and clopidogrel. zMultiple WBA provides 3 parameters: velocity, area under the
curve, and percent platelet inhibition. Area under the curve provides the greatest diagnostic yield.62 Several studies report cutoff values delineating aspirin resistance using
Multiplate.63-65 xCutoff values were adjusted for number of days after preoperative clopidogrel discontinuation and expressed as percentage of the normal range value of ADP test
as indicated by manufacturer (53-122 U [area under the curve]). kGurbel and colleagues66 investigated the prognostic value of thromboelastography (MAadp) in assessment of
ischemic events among patients undergoing percutaneous coronary intervention. MAadp>47 mm was found to be the best predictor of ischemic events (receiver operating area
under the curve, 0.84; 95% CI, 0.78-0.89; P<.0001).
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Clopidogrel resistance Cutoff value for APT resistance
OutcomePlatelet function test POC turnaround time Aspirin Clopidogrel
VerifyNow P2Y12 <10 min Aspirin reaction units>550 P2Y12 resistance units>230 and
platelet inhibition>30%
APT resistance predicted graft
occlusion (RR, 3.6; 95% CI, 2.5-
6.9; P<.001)
Short TEG (Haemonetics Corp) 15 min <50% TEG platelet inhibition <30% TEG platelet inhibition Inclusion criterion was stent
thrombosis
Not reported N/A >1 Ohm Not reported No correlation between APT resistance
and SVG patency
Aspirin reaction units 550 Not reported No correlation between APT resistance
and SVG patency
CEPI clotting time 193 s Not reported SVG occlusion was more prevalent in
subjects with CADP clotting time
88 s (at 6 mo); no correlation with
CEPI
UTxB2 400 pg/mg creatinine Not reported ASA-insensitive TXA2 generation,
measured by UTxB2, predicted
SVG thrombosis
Not reported N/A 30 AUCz Not reported Not reported
TEG platelet mapping (Haemoscope
Corp)
Up to 1 h AA-induced platelet activation>50% ADP-induced platelet activation
>50%
MAadp<42.5 mm predicted increased
postoperative bleeding
Not reported N/A Residual platelet aggregation>20% Not reported Not reported
Residual ADP-induced platelet
aggregation>70%
>3 Ohms
Aperture closure time<193 sec
Aspirin reaction units 550
67.9 ng/mmol of creatinine
Not reported N/A Platelet aggregation>30% despite
in vitro addition of 25 mmol/L ASA
to exclude noncompliance
Not reported Three deaths occurred after 12-mo
follow-up. All were perioperatively
found to be aspirin resistant.
Not reported N/A Platelet aggregation was assessed as
continuous variable without cutoff
for clopidogrel resistance.
Not reported Nonsignificant relationship between
platelet aggregation studies and
chest tube discharge in 24 h was
noted.
Not reported N/A >1 SD above the normal value Not reportedk %MAASA (TEG) higher in patients
with occluded grafts (55 22 vs 22
 17, P¼ .05);WBA%Ohm 6min
low vs high dose (69  25 vs 35 
20, P ¼ .05) higher in patients with
occluded grafts.
Not reported N/A >1 SD above the normal value Not reported
ADP test Multiplate (Dynabyte Gmbh) 9 min Not reported x>60% of lower limit of normal range
(last clopidogrel dose within 1 d);
ADP test>32 U
The last ADP test result before the
operation was significantly
associated (P ¼ .002) with
postoperative bleeding and the need
for postoperative platelet
concentrate transfusions;
thrombotic events not reported.
x>70% of lower limit of normal range
(last clopidogrel dose 2 d); ADP test
>37 U
x>80% of lower limit of normal range
(last clopidogrel dose 3 d before the
test); ADP test>43 U.
xPlatelet aggregation within normal
range (>53 U); last dose of
clopidogrel>4 d
TABLE 1. Continued
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FIGURE 1. Algorithm summarizing management options for patients
with documented APT resistance. APA, Antiplatelet agent; APT, antiplate-
let therapy; hRPR, high residual platelet reactivity; IPA, inhibition of
platelet aggregation; PFT, platelet function test.
Expert Review Gasparovic et alof the antiplatelet drug armamentarium will likely translate
into superior outcomes in the clinical domain. The benefits
of enhanced platelet inhibition must be balanced against an
increased risk of bleeding, which is bound to be its un-
wanted, yet inevitable, corollary.CONCLUSIONS
We advocate the use of point-of-care PFTand tailoring of
APT. Prospective accumulation of data on the clinical
impact of such strategies is sorely needed for them to
become validated on a larger scale.References
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